CLEVELAND: A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that impacts more than 1 in 5,000 people worldwide.
University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD, has announced the formation of a new Department of Pharmacology, Physiology and Drug Development, which merges the Department of Physiology and Department of Pharmacology. This new Department aligns the basic science research efforts of both entities with a strong emphasis on the development of new drug therapies.
Nutritional supplements offer a convenient way to easily increase your daily intake of vitamins, minerals, and other nutrients without making significant lifestyle changes.
A new national survey from The Ohio State University Wexner Medical Center reveals 1 in 4 (25%) of 1,006 adults surveyed would consider using an injectable weight loss medication without consulting their doctor.
In 2022, a team from Children’s Hospital Los Angeles became the first in the world to implant a novel cardiac stent designed specifically for babies and young children. The stent is the first of its kind that can be expanded as a child grows—all the way to adult size.
A new survey from the American Academy of Sleep Medicine reveals that nearly half (45%) of parents have given melatonin to a child under the age of 18 to help him or her sleep.
Scientists have decoded the genetic blueprint of Atractylodes lancea, a prized herb in traditional Chinese medicine. Through comprehensive genome resequencing, the study unveils how natural variations drive the plant's evolution and metabolic adaptations, particularly affecting the production of key medicinal compounds.
Varda Space Industries, Inc., the world's first in-space pharmaceutical processing and hypersonic Earth re-entry logistics company, together with SSPC, the Research Ireland Centre for Pharmaceuticals, today announced a research collaboration that aims to advance mathematical modeling of crystallization in microgravity, the first such framework that considers polymorphism.
Rutgers Health researchers and others find hundreds of young patients receive potentially dangerous medication combinations, raising concerns about prescription practices.
Opeolu Adeoye, MD a professor of emergency medicine at Washington University School of Medicine in St. Louis, led a national clinical trial that found that two anti-coagulant medications are ineffective at improving post-treatment outcomes for stroke patients.
Assistant Professor of Pharmaceutical Sciences Kuo-Ching (KC) Mei from Binghamton University, State University of New York and his team have won the $1.9M Maximizing Investigators’ Research Award (MIRA) for Early Stage Investigators (ESI) from the National Institute of General Medical Sciences to tackle gene therapy challenges.
In a landmark development for environmental conservation, a pioneering plasmonic photocatalyst has been engineered to synergistically degrade the potent pollutants hexavalent chromium (Cr(VI)) and norfloxacin from aquatic environments.
The invention of a tool capable of unlocking previously impossible organic chemical reactions has opened new pathways in the pharmaceutical industry to create effective drugs more quickly.
Since anti-obesity medications have become more widely known and prescribed, they have been touted as game-changing treatments for chronic overweight and obesity. But one common misconception about these medications is that they’re a magic bullet for better health, and it doesn’t necessarily matter what you eat when you’re taking them.
When you pick up a prescription or get a vaccination, it’s paramount that you trust the medication is safe. In the U.S., a system of laws, procedures, and personal responsibility combine to ensure drug safety, or pharmacovigilance.
EVOQ Therapeutics, Inc. (EVOQ) a biopharmaceutical company dedicated to the treatment of autoimmune diseases, announced today the receipt of a $2 million grant from the National Institutes of Health (NIH) to advance novel therapies for autoimmune diseases.
When taken at the first signs of a migraine, before headache pain begins, a drug called ubrogepant may be effective in helping people with migraine go about their daily lives with little or no symptoms, according to a new study published in the August 28, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right